Alejandro (Alex) Barbagelata

Physician, Invasive Cardiologist, Heart Failure, Scientist (Adj Profesor at Duke University), Clinical Trialist. Interested in cardiovascular innovations

[Alejandro (Alex) Barbagelata @barba001barbage]

Cardio kidney metabolic syndrome Guidelines

[JACC Journals @JACCJournals]

The AHA/ACC/ADA/ASN have developed the first-ever guideline aimed at preventing & managing #CKM syndrome, an interconnected set of health conditions that significantly 📈 the risk of multiorgan complications & negative CV outcomes https://t.co/kmUw3woToN #JACC #ClinicalGuidelines

[Alejandro (Alex) Barbagelata @barba001barbage]

Finerenone in non daibetics. Just published NEJM

[Ahmed Bennis MD 🫀 @drbennisahmed]

🔵 FIND-CKD Trial Results are out in @NEJM!
Finerenone vs placebo in non-diabetic #CKD:

A new era for non-diabetic #CKD treatment?

⚠️ Acute dip at month 1 (hemodynamic effect) — then sustained preservation

https://t.co/JF0jn71EV3

[Alejandro (Alex) Barbagelata @barba001barbage]

With muy colleagues Adrian Baranchuk, Luis Aguinaga and ale Meretta at the Argentinean Federation of cardiology congress in Rosario

[Alejandro (Alex) Barbagelata @barba001barbage]

Experimental Drug Yields Dramatic Weight Loss https://t.co/PzauUqMNM5

[Alejandro (Alex) Barbagelata @barba001barbage]

Duscussing the Heart-Liver Axis en Heart Failure, role of the GLP-1 in Taiwan at the APSC with AHA president

[Juan Pinilla @JPinilla_MD]

Great paper with the leadership of Dr. Dandamudi.

We invite you to read our work on Sleep and Breathing.

https://t.co/jjt1tVKPNz

[Alejandro (Alex) Barbagelata @barba001barbage]

Humm . Looks works for everything

[The Lancet @TheLancet]

Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new treatments.

A new study found that GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity: https://t.co/MhUTBf9G7h

[Jon Cole @Joncole23]

If I had to place a bet I would say they are going to cure diabetes / reverse it over the next 25 years

[Alejandro (Alex) Barbagelata @barba001barbage]

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study https://t.co/pWdHgNOPqY

[Alejandro (Alex) Barbagelata @barba001barbage]

Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation | New England Journal of Medicine https://t.co/l6Wjy4yPex

[Alejandro (Alex) Barbagelata @barba001barbage]

Real or AI doctors? https://t.co/Qh4BjrF3j1

[Alejandro (Alex) Barbagelata @barba001barbage]

https://t.co/rnnQPamhmK

[Alejandro (Alex) Barbagelata @barba001barbage]

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors: Cell Metabolism https://t.co/KXLIv1iQ25

[Alejandro (Alex) Barbagelata @barba001barbage]

Six Reasons Why CHAMPION-AF Should Not Change Practice https://t.co/A5x7gRGmzX

[Shikha Jha M.D.🫀 @Shikha_Cardio]

🌟 #ACC2026 Late Breaking Clinical Trials
♥️ ONE LINER SUMMARY: AT A GLANCE 📸
Such an outstanding lineup of Scientific work, innovation acknowledge sharing!🫶
Huge congratulations to all the presenters and trial team members for your hard work and contribution.👏 #LearningTogether
@ACCinTouch @JACCJournals @NEJM @CircAHA @CardioNerds #LBCTs
Dear all - Please share if you like! 😊

[Alejandro (Alex) Barbagelata @barba001barbage]

Exactly. Be also good to know how much data they exclude in the analysis from the procedure itself

[Marios Georgakis @MariosGeorgakis]

After reading the paper, I found it very weird that there is no mention of a higher risk of ischemic stroke with LAAC and you need to dig into Supplementary Table 17 to find the impact on ischemic stroke.

Ischemic stroke prevention is the main reason to implant the device in the first place.

It is very unusuall practice of result reporting for such a large-scale trial.

[Alejandro (Alex) Barbagelata @barba001barbage]

@drjohnm @theheartorg Great comments!

[Alejandro (Alex) Barbagelata @barba001barbage]

@omendiz Dudo que te llame. Costo muy elevada para una evidencia muy escasa. No es para Argentina mi amigo

[Alejandro (Alex) Barbagelata @barba001barbage]

FDA Grants Approval for Abbot's CardioMEMS Hero Device https://t.co/gVGfLFKbCp